But making AbbVie an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of ABBV ...
The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...
AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...
The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.
As AbbVie Ireland’s new general manager, Dana Kendall will oversee the company’s commercial business in the country.
Shares of AbbVie Inc. oscillated between gains and losses Friday as the company’s latest acquisition drew mixed reactions ...
Shares of AbbVie Inc. ABBV inched 0.10% higher to $173.37 Friday, on what proved to be an all-around mixed trading session ...
Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...
The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...
Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie ...
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...